Navigation Links
Next Generation Sequencing: Emerging Clinical Applications and Global Markets
Date:7/25/2013

is timely to examine the clinical segment of the sequencing industry.

 

CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE

 

This report fills a gap in the industry because its sole focus is on clinical applications run on next generation sequencing instruments. The industry is still emerging, so there is little information available regarding the applications for which NGS platforms will be used. The report provides a roadmap for understanding the ways in which next generation sequencing will be used in the diagnostic business during the next five years. It is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in clinical diagnostics. This market report will be useful to many companies involved in the clinical, genetic testing and sequencing industries. It will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip and sample preparation.

 

SCOPE AND FORMAT

 

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2012, 2013 and 2018. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed. The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. LIVE Twitter Chat Featuring Next-Generation Sequencing Expert from The Children’s Hospital of Philadelphia
2. Air Force support for a new generation of lithium-ion batteries
3. Tutela Launches Genesis II - Next Generation Wireless Medical Monitoring System
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
6. DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger
7. Impact with Martin Sheen Introducing Audiences to the Next Generation of Environmental Custodians
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. Clearbridge BioMedics Reveals ClearCell(R) FX, Next Generation Label-free Cancer Cell Enrichment System at ASCO 2013
10. The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments
11. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Chardon, Ohio (PRWEB) March 05, 2015 ... and Gold Development Partner located in Northeast Ohio, today ... chosen e2b teknologies to support its upgrade to the ... As the largest independent group practice of its kind ... base and large volume of transactions, so efficiency and ...
(Date:3/4/2015)... VILLAGE, Nev. , March 4, 2015 PDL BioPharma, ... the adjusted conversion rate for the: , 3.75% ... is 174.8506 shares of common stock per $1,000 principal amount ... The conversion rate for the note is adjusted in ... paid on March 12, 2015, to all stockholders who own shares ...
(Date:3/4/2015)... , March 4, 2015  Brooklyn residents now have ... and chronic pain and injuries. Nunzio Saulle , ... grand opening of his NJS Physical Medicine and Rehabilitation ... on Thursday, March 5, 2015. Health Plus Management, LLC ... is located at 1178 Flatbush Avenue. This new PM&R ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
Breaking Biology Technology:Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... Chief Executive,Officer and a member of the Board of ... President and Chief Executive Officer of,Neurocrine and will continue ... "While this was a very difficult decision for ...
... 14 VIRxSYS Corporation, a,privately held company developing ... Corporation, a privately-owned biotechnology company,focused on the manufacture ... have agreed to settle the pending litigation between,the ... and counterclaims,asserted in the lawsuit, which has been ...
... Patients are ... in the U.S., REHOVOT, Israel and NORTH BRUNSWICK, ... ROSG ), a leader,in the development of microRNA-based diagnostics ... with the Henry Ford,Health System in Detroit, Michigan, to ...
Cached Biology Technology:Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer 2VIRxSYS and Lentigen Announce Litigation Settlement 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 3Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 4
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2
... Washington, D.C. (September 14, 2010) -- Because one ... protein molecules is producing good isolated single crystals, improved ... of genomics and pharmaceutical research. Research reported ... fluorescence correlation spectroscopy (FCS) to investigate the processes at ...
... Biological Sciences Research Council,(BBSRC) have discovered key plant enzymes that ... non-edible parts of plants difficult to extract. The findings, published ... , can be used to improve the viability of sustainable ... The team based at the University of Cambridge, and now ...
... genetic study to compare nuclear DNA of endangered Antillean ... as separate subspecies. Belize,s manatees, however, were found to ... long-term genetic viability. The Central American country of ... manatees and is touted by biologists for its potential ...
Cached Biology News:How do your crystals grow? 2Biofuel from inedible plant material easier to produce following enzyme discovery 2Manatee subspecies genetically confirmed, but diversity challenge looms 2Manatee subspecies genetically confirmed, but diversity challenge looms 3
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
... Diluted Antiserum for RIA, Host: Rabbit ... Immunology Products, Host: Rabbit Antigen ... peptide and 1 2 ... (rat) (H-9295) and ([ 1 2 ...
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
...
Biology Products: